Zhongguo shi yan xue ye xue za zhi · 2015
[Effect of arsenic trioxide on differentiation induction of chronic myeloid leukemia k562 cells and its potential mechanism].
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lyu Fei-Fei, Du Yan, Li Nan-Nan, Wang Wei
Аннотация
OBJECTIVE: This study was to explore the effect of arsenic trioxide (ATO; As(2)O(3)) on differentiation of chronic myeloid leukemia K562 cells and its potential mechanism.
METHODS: ATO with different concentration (0.1, 0.5, 1.0, 2.0, 5.0 µmol/L) were used to treat K562 cells, and MTT assay was used to detect the growth level of K562 cells; Benzidine staining was applied to measure the change of hemoglobin content; flow cytometry (FCM) was conducted to detect the expression of CD41 and GPA on K562 cells; RT-PCR and Western blot were used to measure the mRNA expression of BTG1 and TAL1 and the protein expression of BTG1 and TAL1, respectively.
RESULTS: ATO significantly inhibited the growth of K562 with dose- and time- dependent manners by benzidine staining, the positive rate of K562 cells induced by ATO reached to 17.63% ± 1.18%, which was significantly higher than that of control (2.87% ± 0.63%) (P < 0.01), and GPA, as the specific marker of erythroid cell differentiation, achieved 68.46% ± 3.67%, while it in control was 3.39% ± 0.84% (P < 0.01), besides, the CD41 expression of megakaryocyte increased but not so obvious as GPA. Meanwhile, the differentiation-related transcriptional factors TAL1 and BTG1 mRNA and the corresponding proteins were expressed more highly.
CONCLUSION: ATO can induce the differentiation of K562 cells into erythroid cells and megakaryocyte, which is associated with up-regulation of the related transcription factors TAL1 and BTG1.
METHODS: ATO with different concentration (0.1, 0.5, 1.0, 2.0, 5.0 µmol/L) were used to treat K562 cells, and MTT assay was used to detect the growth level of K562 cells; Benzidine staining was applied to measure the change of hemoglobin content; flow cytometry (FCM) was conducted to detect the expression of CD41 and GPA on K562 cells; RT-PCR and Western blot were used to measure the mRNA expression of BTG1 and TAL1 and the protein expression of BTG1 and TAL1, respectively.
RESULTS: ATO significantly inhibited the growth of K562 with dose- and time- dependent manners by benzidine staining, the positive rate of K562 cells induced by ATO reached to 17.63% ± 1.18%, which was significantly higher than that of control (2.87% ± 0.63%) (P < 0.01), and GPA, as the specific marker of erythroid cell differentiation, achieved 68.46% ± 3.67%, while it in control was 3.39% ± 0.84% (P < 0.01), besides, the CD41 expression of megakaryocyte increased but not so obvious as GPA. Meanwhile, the differentiation-related transcriptional factors TAL1 and BTG1 mRNA and the corresponding proteins were expressed more highly.
CONCLUSION: ATO can induce the differentiation of K562 cells into erythroid cells and megakaryocyte, which is associated with up-regulation of the related transcription factors TAL1 and BTG1.